Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312088577> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4312088577 abstract "Background Substantial data from animal models of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer’s disease (AD) indicate that accumulation of chondroitin sulfate proteoglycans (CSPGs) at sites of CNS damage can lead to inhibition of CNS repair. A CSPG receptor termed protein tyrosine phosphatase sigma (PTPσ) has been implicated in mediating the inhibitory effect of CSPGs. NervGen is developing a first-in-class PTPσ modulator NVG-291, a systemically administered therapeutic peptide derived from the cytoplasmic domain of PTPs, for treatment of nervous system damage. A rodent analogue of NVG-291 was found to improve functional outcomes, axonal regeneration, remyelination and neuroplasticity in animal models of CNS damage. Method Part 1 (SAD portion) enrolled 37 subjects randomly assigned into 6 dose cohorts of placebo or NVG-291. The doses tested exceed the human equivalent doses that showed efficacy in several animal models including SCI and MS. Part 2 (MAD portion) will dose up to 18 subjects randomly assigned into 3 dose cohorts to receive NVG-291 or placebo once-daily for 14 days. CSF will be collected in additional subjects for analysis of NVG-291 concentration and biomarker exploration. Result NVG-291 has been safe and well-tolerated through the 6 SAD cohorts (Part 1). Part 2 will complete in 2022. Part 1/2 results will be presented. Conclusion This Phase 1 study will establish the safety, tolerability, and pharmacokinetics of NVG-291 to support advancement to a clinical trial in patients with AD in 2022." @default.
- W4312088577 created "2023-01-04" @default.
- W4312088577 creator A5003802820 @default.
- W4312088577 creator A5009860624 @default.
- W4312088577 creator A5042836257 @default.
- W4312088577 creator A5066852300 @default.
- W4312088577 creator A5067498610 @default.
- W4312088577 creator A5074108995 @default.
- W4312088577 date "2022-12-01" @default.
- W4312088577 modified "2023-10-16" @default.
- W4312088577 title "A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)" @default.
- W4312088577 doi "https://doi.org/10.1002/alz.059663" @default.
- W4312088577 hasPublicationYear "2022" @default.
- W4312088577 type Work @default.
- W4312088577 citedByCount "0" @default.
- W4312088577 crossrefType "journal-article" @default.
- W4312088577 hasAuthorship W4312088577A5003802820 @default.
- W4312088577 hasAuthorship W4312088577A5009860624 @default.
- W4312088577 hasAuthorship W4312088577A5042836257 @default.
- W4312088577 hasAuthorship W4312088577A5066852300 @default.
- W4312088577 hasAuthorship W4312088577A5067498610 @default.
- W4312088577 hasAuthorship W4312088577A5074108995 @default.
- W4312088577 hasConcept C126322002 @default.
- W4312088577 hasConcept C142724271 @default.
- W4312088577 hasConcept C143998085 @default.
- W4312088577 hasConcept C170493617 @default.
- W4312088577 hasConcept C185592680 @default.
- W4312088577 hasConcept C197934379 @default.
- W4312088577 hasConcept C203014093 @default.
- W4312088577 hasConcept C204787440 @default.
- W4312088577 hasConcept C27081682 @default.
- W4312088577 hasConcept C2777619251 @default.
- W4312088577 hasConcept C2778375690 @default.
- W4312088577 hasConcept C2778609137 @default.
- W4312088577 hasConcept C2780640218 @default.
- W4312088577 hasConcept C2781197716 @default.
- W4312088577 hasConcept C529278444 @default.
- W4312088577 hasConcept C55493867 @default.
- W4312088577 hasConcept C71924100 @default.
- W4312088577 hasConcept C85528070 @default.
- W4312088577 hasConcept C98274493 @default.
- W4312088577 hasConceptScore W4312088577C126322002 @default.
- W4312088577 hasConceptScore W4312088577C142724271 @default.
- W4312088577 hasConceptScore W4312088577C143998085 @default.
- W4312088577 hasConceptScore W4312088577C170493617 @default.
- W4312088577 hasConceptScore W4312088577C185592680 @default.
- W4312088577 hasConceptScore W4312088577C197934379 @default.
- W4312088577 hasConceptScore W4312088577C203014093 @default.
- W4312088577 hasConceptScore W4312088577C204787440 @default.
- W4312088577 hasConceptScore W4312088577C27081682 @default.
- W4312088577 hasConceptScore W4312088577C2777619251 @default.
- W4312088577 hasConceptScore W4312088577C2778375690 @default.
- W4312088577 hasConceptScore W4312088577C2778609137 @default.
- W4312088577 hasConceptScore W4312088577C2780640218 @default.
- W4312088577 hasConceptScore W4312088577C2781197716 @default.
- W4312088577 hasConceptScore W4312088577C529278444 @default.
- W4312088577 hasConceptScore W4312088577C55493867 @default.
- W4312088577 hasConceptScore W4312088577C71924100 @default.
- W4312088577 hasConceptScore W4312088577C85528070 @default.
- W4312088577 hasConceptScore W4312088577C98274493 @default.
- W4312088577 hasIssue "S10" @default.
- W4312088577 hasLocation W43120885771 @default.
- W4312088577 hasOpenAccess W4312088577 @default.
- W4312088577 hasPrimaryLocation W43120885771 @default.
- W4312088577 hasRelatedWork W2022106044 @default.
- W4312088577 hasRelatedWork W2022452208 @default.
- W4312088577 hasRelatedWork W2047057461 @default.
- W4312088577 hasRelatedWork W2052960773 @default.
- W4312088577 hasRelatedWork W2243144343 @default.
- W4312088577 hasRelatedWork W2550781 @default.
- W4312088577 hasRelatedWork W2771462734 @default.
- W4312088577 hasRelatedWork W2772808251 @default.
- W4312088577 hasRelatedWork W3139976826 @default.
- W4312088577 hasRelatedWork W4220714775 @default.
- W4312088577 hasVolume "18" @default.
- W4312088577 isParatext "false" @default.
- W4312088577 isRetracted "false" @default.
- W4312088577 workType "article" @default.